Clinical trials: Attention Deficit Disorder (ADD)
ADHD
Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate efficacy, safety and tolerability of metadoxine (MG01CI) extended release formulation for the treatment of adults diagnosed with ADHD
- Trial name
- NCT01243242
- Testing
- Metadoxine (MG01CI)
- Where
- 2 sites in Israel
- Volunteers
- 120 people
- Sponsor
- Alcobra Ltd.
Attention Deficit Hyperactivity Disorder
A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations
This is a non-interventional study in children and adolescents (ages 6-17 years) with attention deficit hyperactivity disorder (ADHD) to assess CNVs in specific genes involved in glutamatergic signaling and neuronal connectivity.
- Trial name
- NCT03233867
- Where
- United States
- Volunteers
- 2,503 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Attention Deficit Disorder With Hyperactivity
Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD
This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD.
- Trial name
- NCT00151970
- Testing
- Methylphenidate Transdermal System, Concerta
- Volunteers
- 128 people
- Sponsor
- Noven Therapeutics
ADHD
Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17
The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months
- Trial name
- NCT00784654
- Testing
- Lisdexamfetamine dimesylate (LDX)
- Where
- 51 sites in United States, Belgium and 7 more
- Volunteers
- 276 people
- Sponsor
- Shire
Disruptive Behavior Disorder
A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
The primary purpose of this study is to document the long-term safety of an oral formulation of risperidone in the treatment of children and adolescents with conduct and other disruptive behavior disorders.
- Trial name
- NCT00236470
- Testing
- risperidone
- Volunteers
- 232 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit Hyperactivity Disorder
Attentin® in Children and Adolescents With ADHD - A Non-interventional Study
The practicality of most ADHD medications is not or only moderately examined under long term routine conditions. Therefore, in this multi-centre, multi-national prospective non-interventional study, a recommended follow-up time…
- Trial name
- Attention (NCT02801604)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
ADHD
Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)
The goal of this clinical trial is to evaluate the efficacy and safety of NRCT-101SR compared to placebo in adult patients with ADHD aged 18 years and older.
- Trial name
- NCT05683249
- Testing
- NRCT-101-SR
- Where
- 9 sites in United States
- Volunteers
- 223 people
- Sponsor
- Neurocentria, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
This study is a multi-center, randomized, double-blind, placebo-controlled, phase 3 study of MDX (1400 mg daily) for 10 weeks compared with placebo in adults with ADHD.
- Trial name
- NCT02477748
- Testing
- MDX
- Where
- 38 sites in United States, Israel
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- Alcobra Ltd.
Attention Deficit Hyperactivity Disorder (ADHD)
Drug Use Study With Intuniv® in Australia
This study will evaluate and analyze prescribing behaviors of physicians and determine whether Intuniv was correctly prescribed in Australia.
- Trial name
- NCT04866030
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- Shire
ADHD
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
- Trial name
- NCT03618030
- Testing
- PRC-063 oral capsules
- Where
- 8 sites in United States
- Volunteers
- 288 people
- Sponsor
- Purdue Pharma, Canada
Attention Deficit Hyperactivity Disorder (ADHD)
A Long-term Trial of EB-1020 in Adult Patients With ADHD
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan
- Trial name
- NCT06926829
- Testing
- EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg
- Where
- Japan
- Volunteers
- 180 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT03605849
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD
Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
To assess the efficacy and safety of efficacy of MTS compared to placebo
- Trial name
- NCT00499863
- Testing
- methylphenidate transdermal system
- Where
- 32 sites in United States
- Volunteers
- 217 people
- Sponsor
- Noven Therapeutics
Attention Deficit Hyperactivity Disorder
A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.
The purpose of this study is to evaluate the safety and effectiveness of JNJ-31001074 compared to placebo in adults with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00566449
- Testing
- JNJ-31001074
- Where
- 21 sites in United States
- Volunteers
- 32 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ADHD
Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)
The purpose of this research study is to evaluate the safety, tolerability, effectiveness, and pharmacokinetics (PK) of twice daily oral doses of V81444 in adults with ADHD.
- Trial name
- NCT02253745
- Testing
- V81444
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vernalis (R&D) Ltd
Attention Deficit Disorder With Hyperactivity
Concerta (Methylphenidate) -To-Generic Switch Study
The primary purpose of this study is to identify whether, after adjustment for confounders via stratification on a propensity score and adjustment for calendar year, the combined endpoint consisting of #1 to #4 (1.
- Trial name
- NCT02730572
- Testing
- Concerta, Concerta AG formulation, Concerta EG formulation
- Volunteers
- 1,464 people
- Sponsor
- Janssen Research & Development, LLC
ADHD
Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17
The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.
- Trial name
- NCT00763971
- Testing
- Lisdexamfetamine Dimesylate (LDX), Methylphenidate Hydrochloride
- Where
- 49 sites in Belgium, France and 8 more
- Volunteers
- 336 people
- Sponsor
- Shire
Attention-deficit Hyperactivity Disorder
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
This is a phase 1b, multicenter, open-label, multiple-dose trial in pediatric subjects (4 - 12 years of age, inclusive) with a confirmed diagnosis of ADHD.
- Trial name
- NCT04786730
- Testing
- Centanafadine
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD, ADD
Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder
The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.
- Trial name
- NCT00301236
- Testing
- Dexmethylphenidate HCl extended-release capsules
- Where
- 25 sites in United States
- Volunteers
- 252 people
- Sponsor
- Novartis
Attention Deficit Disorder With Hyperactivity
Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to assess the safety and tolerability of administering SPD503 (Guanfacine hydrochloride) with psychostimulants (amphetamine or methylphenidate) for treatment of ADHD in children and adolescents aged…
- Trial name
- NCT00151996
- Testing
- Methylphenidate + SPD503 (Guanfacine hydrochloride), Amphetamine + SPD503
- Volunteers
- 75 people
- Sponsor
- Shire